Endocrinology-informed neuroimaging in eating disorders: GLP1, orexins, and psilocybin.
Trends in molecular medicine April 1, 2024 DOI: 10.1016/j.molmed.2023.12.001 (opens in new tab) via PubMed
Summary
AI-generated from the abstractNeuroimaging combined with peripheral endocrine measures can reveal the neurobiological drivers of eating disorders such as anorexia nervosa, bulimia nervosa, and binge eating disorder. Orexins/hypocretins, glucagon-like peptide-1 receptor (GLP1R) agonists, and psilocybin are highlighted as promising avenues for future investigation into the underlying mechanisms and potential treatments.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Psilocybin |
| Keywords | Glp1 Eating disorders FMRI Orexin |
| Key finding | Neuroimaging combined with peripheral endocrine measures can provide insights into the neurobiological drivers of eating disorders, and orexins/hypocretins, GLP1R agonists, and psilocybin are highlighted as avenues for investigation. |
Abstract
The neurobiology of eating disorders [EDs; anorexia nervosa (AN), bulimia nervosa (BN), and binge eating disorder (BED)] remains poorly understood. Here, I describe how neuroimaging, accompanied by peripheral endocrine measures, can provide insights into the neurobiological drivers of eating disorders. Orexins/hypocretins, glucagon-like peptide-1 receptor (GLP1R) agonists, and psilocybin are highlighted as avenues for investigation.